[HTML][HTML] PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
X Li, C Wu, N Chen, H Gu, A Yen, L Cao, E Wang… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Glioblastoma multiform (GBM) is the most common malignant glioma of all the brain tumors
and currently effective treatment options are still lacking. GBM is frequently accompanied …
and currently effective treatment options are still lacking. GBM is frequently accompanied …
Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding
A Sami, M Karsy - Tumor Biology, 2013 - Springer
Glioblastoma multiforme (GBM) is a grade IV astrocytoma with a median survival of 12
months despite current multi-modal treatment options. GBM is distinguished …
months despite current multi-modal treatment options. GBM is distinguished …
Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance
Gliomas represent the most common primary brain tumor and among the most aggressive of
cancers. Patients with glioma typically relapse within a year of initial diagnosis. Recurrent …
cancers. Patients with glioma typically relapse within a year of initial diagnosis. Recurrent …
Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM-Could combination therapy checkmate the collusion?
Glioblastoma multiforme is one of the calamitous primary glial brain tumors with extensive
heterogeneity at cellular and molecular levels. While maximal surgical resection trailed by …
heterogeneity at cellular and molecular levels. While maximal surgical resection trailed by …
Targeted therapy for malignant glioma patients: lessons learned and the road ahead
TT Huang, SM Sarkaria, TF Cloughesy, PS Mischel - Neurotherapeutics, 2009 - Elsevier
Molecularly targeted therapies are transforming the care of patients with malignant gliomas,
including glioblastoma, the most common malignant primary brain tumor of adults. With an …
including glioblastoma, the most common malignant primary brain tumor of adults. With an …
mTOR signaling in glioblastoma: lessons learned from bench to bedside
Abstract Phosphatidyl-inositol-3 kinases (PI3Ks) constitute a family of intracellular lipid
kinases that are frequently hyperactivated in glioblastoma. The PI3K complex links growth …
kinases that are frequently hyperactivated in glioblastoma. The PI3K complex links growth …
Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development
H Zhao, J Wang, W Shao, C Wu, Z Chen, ST To, W Li - Molecular cancer, 2017 - Springer
Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary
tumor in the central nervous system. One of the most widely used chemotherapeutic drugs …
tumor in the central nervous system. One of the most widely used chemotherapeutic drugs …
Targeting mTOR in glioblastoma: rationale and preclinical/clinical evidence
The mechanistic target of rapamycin (mTOR) drives several physiologic and pathologic
cellular processes and is frequently deregulated in different types of tumors, including …
cellular processes and is frequently deregulated in different types of tumors, including …
Current therapeutic paradigms in glioblastoma
A Quick, D Patel, M Hadziahmetovic… - Reviews on Recent …, 2010 - ingentaconnect.com
Glioblastoma (GBM), a WHO grade IV malignant glioma, is the most common and lethal
adult primary brain tumor. Median survival rates range from 12-15 months. The current …
adult primary brain tumor. Median survival rates range from 12-15 months. The current …
EGFR signals to mTOR through PKC and independently of Akt in glioma
Amplification of the gene encoding the epidermal growth factor (EGF) receptor (EGFR)
occurs commonly in glioblastoma, leading to activation of downstream kinases including …
occurs commonly in glioblastoma, leading to activation of downstream kinases including …